LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects

Contributed by: Business Wire

Logo

Tags

Biotechnology

Medical Devices

Health

Optical

Clinical Trials

LIGHTSITE IIIB Extension Trial

More Like This

LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMD Patients to Improve Vision

LumiThera Provides Update on FDA Review of Valeda Treatment for Dry AMD Patients

LumiThera Announces Initiation of EUROLIGHT Registry Study to Evaluate Long-term Benefits of Photobiomodulation (PBM) Treatment using the Valeda® Light Delivery System in Patients with Dry Age-Related Macular Degeneration (AMD)

LumiThera Announces First CPT Code to Report Photobiomodulation Therapy in Retinal Disease – First Step Toward Reimbursement

Aviceda Therapeutics Announces Topline Data from Part 1 of the Phase 2/3 SIGLEC Clinical Trial for AVD-104, Demonstrating Positive Safety and Early Clinical Efficacy in Patients with Geographic Atrophy

Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease (Graphic: Business Wire)

Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease

Beacon Therapeutics Announces Positive Phase 2 Interim 6-Month Data from DAWN Trial of Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2025

LUMA Vision Co-Founders, CEO Fionn Lahart (right) and Chief Technology Officer Christoph Hennersperger (left). (Photo: Business Wire)

LUMA Vision Announces $22 Million in New Financing to Secure FDA Approval and Advance Development of 4D Cardiac Imaging and Navigation Platform